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Abstract
Here we show a screening of compounds for Neurokinin 1 receptor regulation using Nomad technology through arrestin pathway. The Nomad biosensor localization is in the Plasma Membrane but the GPCR 
activation leads to a modication in its structural folding that promotes its vesicularization. In this work we have screened a library of 600 compounds. Substance P and L733-060 compounds were used as 
agonist and inhibitor control for this model. After the screening campaign, positive compounds were chosen for further testing, based on the strength of the initial response and the lack of cytotoxicity. Our 
results indicated that this model is a valid strategy for drug screening.
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Figure 1. Schematic representation of the Nomad biosensor functioning in living cells. Nomad biosensor is a uorescent fusion polypeptide capable of 
changing its localization within the cell from the cell cytoplasmic membrane to retention vesicles, upon an increase in the concentration of second messengers 
within the cell cytoplasm. A second messenger concentration increase leads to a  change in the spatial folding of  Nomad Biosensor that promotes a cellular 
localization change. High-content screening (HCS) in Nomad Biosensors using living cells is a very useful tool in biological research to discover and optimize new 
drug candidates. 
Methods and Materials
Cultured cells: 
U2OS based model cells were cultured into 96 wells Imaging Plates BD at  15.103 cells/well in 200 µl of DMEM F12 10% FBS and incubated at 37ºC and 5% CO2.   After 16 hours, the cells were treated 
in OptiMEM and incubated with the compounds during 24 hours.
Image acquisition:
The cells were xed with formaldehyde solution (3.7 wt. %, 20 minutes).  Nuclei were stained using DAPI (2 ng/ml) and the uorescence was measured using a BD Pathway 855 High-Content 
Bioimager from Becton Dickinson. To detect DAPI, the lters used were 380/10 and 460/10 nm for excitation and emission respectively and to detect arrestin Nomad, the lters were 590/20 nm 
and 665/8 nm. The images where obtained with an objective of 20X, taking 9 pictures of each well. Cell quantication was performed delimitating the region of interest of the nuclei (stained with 
DAPI) using Attovision software (Becton Dickinson) and after quantication, the average of each of the 5 replicates was performed. Vesicles quantication was also performed using AttoVision 
Software. This software application quantied the granularity per cell and the average of granularity per cell of each well was calculated.  Approximately 500 cells per eld were analyzed.
 
Conclusions
*Nomad  is a uorescent biosensor platform that covers the main 
GPCR signaling pathways, works in living cells and provides accurate 
quantitative results.
*Nomad technology can be used for second messenger and arrestin 
pathway studies.
*Nomad biosensor provides a robust and homogeneous assay that is 
amenable to High Contect Screening with high Z’ values.
*Nomad  cell-based assays require no additional reagents. The 
uorescence signal can be detected on any standard imaging system 
and the results can be obtained  easily using images analysis 
algorithms.
*Nomad technology can be multiplexed for simultaneous 
measurement of second messengers of dierent signaling pathways 
and tagged receptors.
Fig. 5. Screening of 600 compounds library using the NK1R-Arrestin Nomad cell line. Representative 
data of vesicle number per cell normalized to control. Negative control (DMSO) is represented in white and 
positive control (Substance P 10 µM) in green. 
Fig. 2.  Nomad biosensor arrestin pathway subcellular localization. Representative images of the Arrestin Nomad NKR1 cell line show an increment in the vesicle number after 
substance P treatment. This vesicular pattern is inhibited after cellular co-treatment with subtance P (10nM) and L733,060 inhibitor ( 1uM).
-Control- -Substance P 10 nM- -Substance P 10 nM +L733,060 1µM- Fig.6.  Cellular viability assessment.  Toxicity levels were determined as a % of cell dead with respect to the 
negative control. The positive control (Substance P) is represented in green and the negative control is 
represented in white. 
Fig.7.  Positive compounds and viability relationship  . The  compounds that show an increment in the 
arrestin pathway activation are represented in black and the cell viability percentage is represented in grey 
with red edge. The positive control (Substance P) is represented in green spots and the negative control 
(DMSO) is represented in white.
Fig.3 Nomad Biosensor Arrestin pathway dose-response  curve of the 
agonist Substance P using NKR1-Arrestin Nomad cell line. To determine the 
EC50 value for Substance P, cells were treated with a range of concentrations 
from 1 µM to 0.1 fM during 24h. Data from measurements were tted to a 
sigmoid 4-parameter t logistic model (sigmoidal) with Sigma Plot 11.0 
software. Error bars represent the standard deviation among 5 replicate wells. 
EC50 for Substance-P was 2,73.10
-9 M and Z’  factor for this experiment was 0.82 
+/-0.01.
Fig.4 Arrestin pathway Nomad biosensor dose -response  curve of the 
inhibitor L733,060 using NKR1-Arrestin Nomad cell line. To determine the 
EC50 value for L733,060, cells were co-treated with a constant concentration of 
10nM of Substance P and a range of concentrations from 10 µM to 0.1 nM of 
L733,060 during 24h. Data from measurements were tted to a sigmoid 
4-parameter t logistic model (sigmoidal) with Sigma Plot 11.0 software. Error 
bars represent the standard deviation among 5 replicate wells. IC50 for 
L733,060 was 3,79.10-7 M and Z’  factor for this experiment was 0.70 +/-0.01.
